Independent directory Public ClinicalTrials.gov records United States
Condition Directory

Lung Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Lung Cancer. Browse Lung Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 16, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
4378
Shown on this page
12
Current sort
Recently updated
Condition scope
Lung Cancer
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Lung Cancer studies are organized in the registry

The registry splits lung cancer records between non-small cell (NSCLC) and small cell (SCLC) disease, and a large share of NSCLC studies are organized around a biomarker rather than the diagnosis alone. If a mutation or marker drives your search, query it directly — it typically appears verbatim in titles. A dedicated non-small cell lung cancer page is also available in this directory.

Terms that often appear in related listings

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Lung Cancer. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 253–264 of 4,378 matching trials for Lung Cancer.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Conditions
Small Cell Lung Carcinoma (SCLC)
Interventions
BI 764532, Carboplatin, Etoposide, Atezolizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Orlando, Florida • Atlanta, Georgia
Recruiting Phase 1 Interventional

DK222 Study at Hopkins

NCT07140315
Conditions
Non-Small Cell Lung Cancer, Urothelial Cancer
Interventions
[18F]DK222 radiotracer
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Lung Cancer, Non Small Cell Lung Cancer
Interventions
Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Duarte, California • Aurora, Colorado • Ann Arbor, Michigan
Conditions
Malignancy, Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Testicular Cancer, Thymoma, Ovarian Cancer, Osteosarcoma
Interventions
palifosfamide-tris
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Indianapolis, Indiana • Lafayette, Indiana • Muncie, Indiana + 1 more
Conditions
Brain Metastases, Small Cell Lung Cancer
Interventions
Stereotactic Radiation
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer, Advanced Solid Tumors
Interventions
PHN-012
Drug
Lead sponsor
Pheon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 8 more
Conditions
Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS)
Interventions
NT-175
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more
Conditions
Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Interventions
obrixtamig, atezolizumab, carboplatin, etoposide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Mobile, Alabama • Little Rock, Arkansas • Hialeah, Florida + 14 more
Conditions
Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
Interventions
AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Phoenix, Arizona • Jacksonville, Florida • Lake City, Florida + 8 more
Conditions
Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer, Stomach Cancer, Cancer
Interventions
IM-1617
Drug
Lead sponsor
Immunome, Inc.
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
New Haven, Connecticut • Sarasota, Florida • Boston, Massachusetts + 1 more
Conditions
Brain Metastases
Interventions
Whole brain radiation, Stereotactic radiation (SRS)
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
Interventions
Obrixtamig, ZL-1310, Atezolizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 1 more

About this Lung Cancer clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Lung Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lung Cancer.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Lung Cancer.